Adamas to Present at Upcoming Healthcare Conferences

EMERYVILLE, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. ADMS, a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company's Chief Executive Officer, is scheduled to present at the following investor conferences:

  • SVB Leerink Global Healthcare Conference on Thursday, February 27 at 9:00-9:25 a.m. ET

    (6:00 a.m. PT)
  • Cowen Annual Healthcare Conference on Wednesday, March 4 at 9:20 a.m.-9:50 a.m. ET

    (6:20 a.m. PT)

The presentations will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. An archived version of the webcast will be available via replay for 30 days following the presentations.

About Adamas Pharmaceuticals, Inc.

At Adamas, our purpose and vision are clear: deliver innovative medicines that make a clinically meaningful difference for patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit www.adamaspharma.com.

Contact:

Investors:

Peter Vozzo

Managing Director, Westwicke

443-213-0505

peter.vozzo@westwicke.com

Media:

Sarah Mathieson

Vice President of Corporate Communications

510-450-3528

smathieson@adamaspharma.com

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!